Li Qiu-Yue, Hou Cheng-Zhi, Yang Li-Ping, Chu Xue-Lei, Wang Yuan, Zhang Ping, Zhao Yong
Wang Jing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China.
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Evid Based Complement Alternat Med. 2020 Jul 31;2020:2658795. doi: 10.1155/2020/2658795. eCollection 2020.
Ginseng, a traditional Chinese medicine, was used to prevent and treat many diseases such as diabetes, inflammation, and cancer. In recent years, there are some reports about the treatment of lung adenocarcinoma with ginseng monomer compounds, but there is no systematic study on the related core targets and mechanism of ginseng in the treatment of lung adenocarcinoma up to now. Therefore, this study systematically and comprehensively studied the molecular mechanism of ginseng in the treatment of lung adenocarcinoma based on network pharmacology and further proved the potential targets by A549 cell experiments for the first time.
The targets of disease and drug were obtained from Gene database. Subsequently, the compound-target network was constructed, and the core potential targets were screened out by plug-in into Cytoscape. Furthermore, the core targets and mechanism of ginseng in the treatment of lung adenocarcinoma were verified by MTT test, cell scratch test, immunohistochemistry, and qRT-PCR.
1791 disease targets and 144 drug targets were obtained by searching the Gene database. Meanwhile, 15 core targets were screened out: JUN, MAPK8, PTGS2, CASP3, VEGFA, MMP9, AKT1, TNF, FN1, FOS, MMP782, IL-1, IL-2, ICAM1, and HMOX1. The results of cell experiments indicate that ginseng could treat lung adenocarcinoma by cell proliferation, migration, and apoptosis. In addition, according to the results of the 15 core targets by qRT-PCR, JUN, IL-1, IL-2, ICAM1, HMOX1, MMP9, and MMP2 are upregulated core targets, while PTGS2 and TNF are downregulated core targets.
This study systematically and comprehensively studied 15 core targets by network pharmacology for the first time. Subsequently, it is verified that 9 core targets for ginseng treatment of lung adenocarcinoma, namely, JUN, IL-1, IL-2, ICAM1, HMOX1, MMP9, MMP2, PTGS2, and TNF, are closely related to the proliferation, migration, and apoptosis of lung adenocarcinoma cells. This study has reference value for the clinical application of ginseng in the treatment of lung adenocarcinoma.
人参作为一种传统中药，被用于预防和治疗多种疾病，如糖尿病、炎症和癌症。近年来，有一些关于人参单体化合物治疗肺腺癌的报道，但迄今为止，尚未有人参治疗肺腺癌相关核心靶点及机制的系统研究。因此，本研究基于网络药理学系统全面地研究了人参治疗肺腺癌的分子机制，并首次通过A549细胞实验对潜在靶点进行了验证。
从基因数据库获取疾病和药物的靶点。随后，构建化合物-靶点网络，并通过Cytoscape插件筛选出核心潜在靶点。此外，通过MTT试验、细胞划痕试验、免疫组织化学和qRT-PCR验证人参治疗肺腺癌的核心靶点和机制。
通过检索基因数据库获得1791个疾病靶点和144个药物靶点。同时，筛选出15个核心靶点：JUN、MAPK8、PTGS2、CASP3、VEGFA、MMP9、AKT1、TNF、FN1、FOS、MMP782、IL-1、IL-2、ICAM1和HMOX1。细胞实验结果表明，人参可通过细胞增殖、迁移和凋亡来治疗肺腺癌。此外，根据qRT-PCR检测15个核心靶点的结果，JUN、IL-1、IL-2、ICAM1、HMOX1、MMP9和MMP2是上调的核心靶点，而PTGS2和TNF是下调的核心靶点。
本研究首次通过网络药理学系统全面地研究了15个核心靶点。随后，验证了人参治疗肺腺癌的9个核心靶点，即JUN、IL-1、IL-2、ICAM1、HMOX1、MMP9、MMP2、PTGS2和TNF，它们与肺腺癌细胞的增殖、迁移和凋亡密切相关。本研究对人参在肺腺癌治疗中的临床应用具有参考价值。
